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LONG ACTING, REVERSIBLE VETERINARY

e.g., a single intravenous administration of 300 mg of
xylaZine in an adult horse produces moderate sedation and

SEDATIVE AND ANALGESIC AND METHOD
OF USE

analgesia lasting from betWeen about 30 to about 60 min
utes. Therefore, there exists a need in the art for a long acting

sedative and analgesic Which can produce profound sedation
and analgesia for longer periods of time folloWing a single

This application claims the bene?t of priority in US.
Provisional Application Ser. No. 60/206,625, ?led on May
24, 2000.

administration of the active.

Upon administration of the alpha-2-agonists, horses typi
FIELD OF INVENTION

cally assume a Wide stance With the head extended and

The present invention relates to the ?eld of veterinary
medicine and to compositions and methods of use for rapid

loWered (ptosis). In male horses, some relaxation of the
penis may occur and the loWer lip becomes ?accid. Muscle
relaxation and ataxia may be severe, particularly When large
doses are administered. The effects of alpha-2-adreno recep

acting reversible sedatives, tranquilizers and analgesics in
animals. In particular, the present invention relates to a rapid

tor agonists can be speci?cally antagoniZed (reversed) by the
administration of and alpha-2-adreno receptor antagonist

acting reversible sedative and analgesic having 0t adrenergic
agonist activity that is adapted for use in the standing

tice, e.g., equine and bovine medicine and surgery, has

(Hubbell J. A. E. and Muir W. W. Standing Chemical
Restraint p. 1874192 in Equine Internal Medicine by Reed
S. M and Bayly W. M, 1997)
Central alpha-2-adrenergic agonist cross the blood-brain
barrier and stimulate alpha-2-adrenergic receptors in the
vasomotor region of the brainstem. Stimulation Of these
receptors decreases sympathetic tone, brain turnover of

incorporated various diagnostic, therapeutic and surgical

norepinephrine and central sympathetic out?oW and activity

animal.
BACKGROUND OF THE INVENTION
20

Veterinary medicine and especially in large animal prac
procedures into the daily routine of the large animal prac
titioner. Many of these procedures are greatly facilitated and

of the preganglionic sympathetic nerves. The net effect is a
25

can be accomplished in the standing animal if the animal

remains clam, motionless, and virtually pain free. An addi
tional consideration is that it may also be bene?cial to calm
the animal, e.g., the coW or horse, before bringing it into

proximity of expensive equipment or to minimiZe the poten
tial for human injury.
Commonly used are sedatives Which have a calming
effect and tranquiliZers Which are a class of drugs used in the
treatment of anxiety states. The goal of sedative and tran
quiliZer administration is to eliminate fear, produce a calm

30

reduction in norepinephrine release. Central alpha-2-adren
ergic agonist may also stimulate the peripheral alpha-2
adrenergic receptors that mediate vasoconstriction. The
usual physiologic effect is a decrease in peripheral resistance
and sloWing of the heart rate; hoWever, output is either
unchanged or mildly decreased. Preservation of cardiovas

cular re?exes prevents postural hypertension.
In human medicine, a variety of guanidine derivatives
have been used clinically as anti-hypertensive agents,
35

ing effect, reduce resistance to manipulation, and, to the

including clonidine, guanabenZ, guanacline, guanadrel, gua
naZodine, guanethidine, guanfacine and guanochlor, guan
oxabenZ and guanoxan.

extent there is an analgesic effect of the drug, to ideally

GuanabenZ (l-[2,6-dichlorobenZylidine-amino]-3-guani

eliminate pain. Generally, users or user facilities of such

dine) is an anti-hypertensive drug Whose mechanism of
action is an agonistic stimulatory effect of the central alpha-2
adrenergic receptors in the cardiovascular regulatory centers
in the brainstem and spinal cord. Its therapeutic effects in

sedatives, tranquiliZers and analgesics are veterinary hospi
tals, veterinarians Working under ?eld conditions, animal

40

control facilities, humane societies, Zoos, researchers and
the like.
Classically, sedatives are a distinct groups of drugs based
on their central nervous system (CNS) site of action. Seda
tives are classically considered as agents that act at the

humans include a reduction in sympathetic tone (a reduction
in heart rate and cardiac output), an increase in parasympa
thetic tone (a reduction in heart rate and cardiac output) and

cortical level and, if given in suf?cient quantities, Will

vasodilation (a relaxation of capacitance vessels and reduc
tion in total peripheral resistance). GuanabenZ is currently

produce CNS depression to the point of hypnosis (arti?cial
sleep). TranquiliZers act at the sub-cortical levels, particu
larly at the reticular activating system, effectively ?ltering

marketed in human medicine in the general class of medi
cines called antihypertensives. It is used to treat high blood

afferent and efferent nervous system activity. Increasing

45

50

pressure (hypertension). GuanabenZ acetate is available on
the market as 4 and 8 mg tablets to be taken orally, e.g., as

doses of tranquiliZers produce greater degrees of calming

WYTENSIN® (Wyeth-Ayerst, Alexandria, Va.)

but do not produce hypnosis. In practical use in animals,
drugs acting at different levels of the CNS have been used

Certain uses of guanabenZ have been previously disclosed
in the art. For example, US. Pat. No. 4,060,640, to Kodama
et al., describes guanabenZ, and its related compounds, as

to obtain the same result, thus the distinction often has
become blurred and the term sedative-tranquiliZer has
evolved.

55

excitability and induce sedation, overcoming psychic

Alpha-2-adreno receptor agonists produce sedation,

depression in humans.

muscle relaxation and analgesia When administered intrave

nously or intramuscularly. Alpha-2-adreno receptor agonists
are used to provide standing chemical restraint for various
procedures, to provide analgesia, and to act as sedatives

prior to anesthesia. The most commonly used alpha-2
agonists used, e.g., in the horse, are xylaZine, detomidine
and romi?dine. All produce dose-dependent sedation and
muscle relaxation Whereas only xylaZine and detomidine
possess analgesic properties. The duration of action of these

alpha-2-adreno receptor agonists, hoWever is typically short,

being central nervous system depressants that reduce hyper

60

US. Pat. No. 5,958,933 to Naftchi discloses guanabenZ,
as part of a drug combination, as being a neurologically
active compound that When administered in an appropriate
dosage amount is suf?cient to restore neurological function

or control spasticity in humans suffering from injury to the
central nervous system.

US. Pat. No. 4,742,054 to Naftchi discloses guanabenZ to
65

have a restorative effect on the central nervous system,

especially in the treatment in mammals of motor and sensory
functional losses due to the traumatic injury to the spinal

US 7,074,834 B2
4
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Another object of the invention is to provide a novel

cord. GuanabenZ is described as being an effective anaes
thetic compound and for use in a method for treating a

veterinary composition comprising an 0t adrenergic receptor

mammal having a damaged central nervous system.
US. Pat. No. 5,635,204 to GevirtZ et al. discloses gua
nabenZ, in combination With other drugs at a particular
dosage as being an effective anaesthetic.

agonist, e.g., a guanidine derivative, and method of use
comprising a single administration of a pharmaceutically
effective amount of said composition to thereby produce a
rapid onset and longer lasting sedation and/ or analgesia in a

standing large animal than is currently available to the
veterinary medical profession and Which has selective

US. Pat. No. 5,958,933, to Naftchi describes oral over

dosage of guanabenZ, as not being reported to result in

reversibility.

anesthesia; the incidents Were recorded as hypotension,

A further object of the invention is to provide a novel

somnolence, lethargy, irritability, myosis and bradycardia in

veterinary composition comprised of an 0t adrenergic recep

young children.

tor agonist, e.g., a guanidine derivative, and method of use
comprising a single administration of a pharmaceutically
effective amount of said composition to thereby produce a

In veterinary medical applications, equine racetrack vet
erinarians have previously used an 8 mg tablet of guanabenZ,
crushed and dissolved in Water, and injected the resultant

rapid onset and longer lasting means for chemical restraint
in a standing large animal than is currently available to the
veterinary medical profession and Which has selective

solution intravenously into horses prior to racing. The ratio
nale behind this administration is that it reduces the blood

pressure in the horse’s pulmonary circulatory tract and
thereby reduces the incidence and/or severity of exercise

reversibility.

induced pulmonary hemorrhage (EIPH) in the horse.
Current available sedatives and tranquilizers such as the
aforementioned xylaZine and detomidine can produce side
effects such as sinus bradychardia and ?rst or second degree
atrioventricular block (Bohart G. Anesthesia of Horses in the

20

FIG. 1 is a plot of head ptosis response in a horse

administered intravenous guanabenZ (100 mg, 0.2 mg/kg);
FIG. 2 is a plot of rapid onset of analgesia response in a

Field in Current Therapy in Equine Medicine by Robinson

horse folloWing administration of intravenous guanabenZ
(100 mg, 0.2 mg/kg); and

N. E, 1998.). Therefor there exists a need in the art for a safe,

effective oral, intravenous, or intramuscular compound for

FIG. 3 plots, in a horse administered intravenous guana

the standing sedation, tranquiliZation and analgesic effect of

benZ (100 mg, 0.2 mg/kg), (a) blood glucose levels (mg/D1);

larger mammals that does not produce the adverse side

(b) urine production (ml); and (c) urine speci?c gravity.

effects seen With current sedatives/tranquilizers.

Prior to the present invention guanidine derivatives, and
in particular guanabenZ and its analogs, have not been
reported as useful as a standing sedative, tranquiliZer and
analgesic combination When used in horses and loWer mam
mals at certain dosages.

30

DETAILED DESCRIPTION OF THE
INVENTION
The present invention relates to a neW veterinary medical
35

OBJECTS OF THE INVENTION

Accordingly, it is an object of the invention to provide a

veterinary composition in unit dosage form comprised of a
guanidine derivative, e.g., guanabenZ acetate, for adminis

40

45

As set forth in the teachings herein, guanabenZ and the
related guanidine derivatives that possess 0t adrenergic
50

In particular, one object of the invention is to provide a
composition and method for producing a rapid onset of
sedation and analgesia in a standing animal, e.g., a large
animal such as a horse, coW, sheep, pig, goat or the like that

receptor agonist effects have utility as safe, effective, long
lasting and rapidly reversible sedatives and/or tranquiliZers
and/or analgesics in other domestic animal species including
but not limited to bovines, ovines, canines, and felines and
other mammalian and domestic animal species requiring

55

Likewise, another object of the invention is to provide a
novel veterinary composition comprised of a derivative of

the guanidine family of compounds, Wherein said derivative
possesses 0t adrenergic receptor agonist activity, e.g., gua
nabenZ acetate, for administration to animals for the induc
tion of a rapid onset sedation and analgesia in the subject

benZ and guanabenZ acetate, in providing a sedative, tran
quiliZer and analgesic effect not only in horses but also loWer
mammals by, e.g., intravenous injection of the aqueous
solution of guanabenZ or a derivative thereof into the subject
animal.

analgesia in an animal by administering in a single dose a
pharmaceutically effective amount of a composition com

is selectively reversible.

control high blood pressure), Wherein the invention provides
compositions thereof for producing a sedative, tranquiliZer
and analgesic effect in primarily horses but also in other
animal species. Thus, the present invention relates generally

family of compounds (guanidine derivatives), e.g., guana

lasting sedation and analgesia in the subject animal the
effects of Which are capable of being selectively reversed.

prised of a guanidine derivative, e.g., guanabenZ acetate, to
the subject animal.

use for guanidine derivatives, e.g., guanabenZ and/or gua
nabenZ acetate (an anti-hypertensive drug used in humans to

to novel compositions and methods of use for the guanidine

tration to animals for the induction of a rapid onset and long

Another object of the invention, is to provide a method of
producing a rapid onset and long lasting sedation and

BRIEF DESCRIPTION OF THE DRAWINGS

60

long acting, safe effective and rapidly reversible sedation
and/or tranquiliZation and/or analgesia.
Additional objects, advantages and other novel features of
the invention Will be set forth in part in the description that
folloWs and in part Will become apparent to those skilled in
the art upon examination of the foregoing or may be learned
With the practice of the invention. Certain patents and

animal the effects of Which are capable of being selectively

printed publications are cited throughout the instant speci

reversed.
In particular, one object of the invention is to provide a
composition and method for producing a rapid onset and

publications are hereby incorporated herein in their entirety
by reference.

long lasting sedation and/or analgesia in an animal Which is

selectively reversible.

?cation. The contents of these cited patents and printed
65

As used herein by “rapid onset” is meant to include the
time interval from administration of the active, e.g., guana

US 7,074,834 B2
5
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benZ acetate, until the drug begins to take effect and produce
the intended response, e.g., sedation and/or tranquiliZation
and /or analgesia. For the compositions disclosed herein, this
time interval typically ranges from betWeen about 1 minute

that this family of drugs has utility as a safe, effective long

acting and rapidly reversible sedative, tranquiliZer and anal
gesic in the horse.
In line With the foregoing, it is Within the contemplation
of the present invention to employ guanabenZ or a guanidine

to about 30 minutes. As one of skill in the art can appreciate,
the length of time for onset of action can vary, e. g., depend

derivative as a sedative, tranquiliZer or analgesic. A deriva
tive being quali?ed as a chemical substance derived from
another substance either directly or by modi?cation or

ing upon the route of administration, the species, age, siZe,
and health status of the animal and the like. In the adult

partial substitution. It is important that the guanidine deriva
tive possess the requesite 0t adrenergic receptor agonist
activity. Examples of other suitable guanidine derivatives

horse, for example, the clinical signs of sedation Will begin
to appear Within 143 minutes following a single intravenous
administration of about 100 mg of guanabenZ or guanabenZ

include but are not limited to:

acetate.

GuanabenZ-2-[(2,6-dichlorophenyl)methylene]

Likewise, by “sedation” is generally meant the act or
process of calming or quieting an animal and may, in some

Guanadine sulfate-[2-(3 ,6-dihydro -4 -methyl- 1 (2H)-pyridyl)
ethyl] guanidine sulfate
Guanadrel-( l ,4-dioxaspiro [4,5] dec -2 -ylmethyl)guanidine

instances be used synonymously With the term “tranquiliZa
tion.” The term “tranquiliZation” as used herein generally

sulfate

means the act or process of depressing the function of the

central nervous system, relieving anxiety and inducing a
state of calmness in the conscious animal.
The term “analgesia” or “analgesic” is meant to include
any conscious relief from a painful stimulus in an animal. In
general, an analgesic is an agent that alleviates pain or
reduces the sensation of pain Without causing loss of con

20

sciousness. The term “long lasting” is generally meant to

25

dine
Zine carboximidamide sulfate

GuanoxabenZ-2-[(2,6-dichlorophenyl)methylene] -N-hy
ethyl)guanidine

establishment of this time interval is subjective but is readily

acid) as Well as isomers (the possession by tWo or more

distinct compounds of the same molecular formula, each
molecule possessing an identical number of atoms of each
element but in different arrangement) of the above men
tioned compounds or other guanidine derivatives may be

upon the route of administration, the species, age, siZe, and
health status of the animal and the like. In the adult horse,

for example, the clinical signs of sedation Will begin to
35

acetate and the duration of action is up to about 4 hours.

as long as the derivative selected possesses su?icient 0t

adrenergic receptor agonist activity.
40

related arts. Therefore, although the guanabenZ for example,
is conveniently administered intravenously, depending on
the circumstances, the pharmaceutical composition may be
administered, e.g., orally, intramuscularly, intravenously or
by other routes knoWn to those skilled in this art.

Compositions suitable for oral administration, include,
e.g., suspensions, tablets, capsules, gels, pastes, boluses, or
preparations in the form of poWders, granules, or pellets.
50

surprising discovery that guanabenZ acetate, after a single

Presently preferred orally administered compositions
according to the invention can include suspensions and

intravenous dose of about 0.2 milligrams per kilogram per
horse, produces a rapid onset of sedation and/or, tranquil
iZation and/or analgesia in the standing horse. After such a
dose, profound sedation and head ptosis appear Within one

The present compositions may be administered by routes
Well knoWn to those skilled in veterinary medicine ant the

produce a rapid onset and long lasting sedation and analge
sia. The compositions provided by the present invention are
designed to overcome the shortcomings of currently avail
able veterinary sedatives, tranquilizers or analgesics and
provide a more effective and longer lasting sedation and/or
analgesia and/or means of chemical restraint, the effects of
Which may be rapidly reversed When desired.
In one embodiment, the present invention provides the

used in the compositions and methods provided by the
invention. It is speci?cally contemplated that any pharma
ceutically acceptable derivative of guanidine or the afore
mentioned compounds are Within the scope of the invention

The instant invention involves, in a preferred embodi
ment, methods for the administration of a novel veterinary

composition comprising a guanidine derivative, e.g., gua

droxyhydraZine carboximidamide
Guanoxan
sulfate-(2,3-dihydro- l ,4-benZodioxin-2 -ylm
In a similar manner, salts (any compound of a base or an

ascertainable in the hands of the skilled artisan. Of course
the duration of action of the active can vary, e. g., depending

nabenZ acetate, in a pharmacutically effective amount by
intravenous, intramuscular, oral or other administration to

Guanacydine-N"-cyano -N-(l , l -dimethylpropyl)guanidine
Guanethidine- [2 -hexahydro -l (2H)-aZocinyl)ethyl] guani -

Guanochlor sulfate-2-[2-(2,6-dichlorophenoxy)ethyl]hydra

include the time interval from the onset of effect of the active
until the effect has Waned to a subclinical level. Thus, the

appear Within 143 minutes folloWing a single intravenous
administration of about 100 mg of guanabenZ or guanabenZ

hydraZin

ecarboximidamide

tablets and paste formulations. Alternatively, and presently
preferred, as set forth herein, the compositions of the inven
tion may be formulated for parenteral administration, e.g.,
55

by intramuscular, intraperitoneal, or intravenous injection.

minute and is maintained for up to four hours Which is of

Pharmaceutically acceptable carriers present in the com

considerably longer longer duration than currently available

positions of the present invention are materials recom

0t arenergic receptor agonists, e.g., xalaZine and detomidine.
This sedation and head ptosis response is rapidly reversible
by intravenous administration of an alpha-2 adrenoceptor

mended for the purpose of administering the medicament in
the desired dosage form. These may be liquid, solid, or
60

blocker (antagonist), e.g., yohimbine.

acceptable and are compatible With the active ingredients.
The same applies for any added excipients, solvents of the

These sedation and analgesic responses can be associated

active, buffers, preservatives and the like.

With a hyperglycemic response Which in turn causes an

For oral administration, ?ne poWders or granules may

increased urine volume (diuresis) and a concomitant reduc

tion in urine speci?c gravity. These pharmacological
responses have not previously been described for guanabenZ
or other guanidine derivatives in the horse, and they shoW

gaseous materials, Which are otherWise inert or medically

65

contain diluting agents, for example, calcium carbonate,
calcium phosphate, mineral carriers, etc., disbursing and/or
surface active agents, for example, polysorbates, and may be

US 7,074,834 B2
7
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presented in a drench, in Water or in a syrup, in a bolus,
paste, or in capsules or sachets in the dry state or in a
non-aqueous suspension, or in a suspension in Water or

position comprised of a pharmaceutically effective amount
of a guanidine derivative is specially adapted for oral,
intramuscular or intravenous administration. As set forth

syrup. Intravenous and intramuscular preparations may, e.g.,

above, it can be appreciated by the skilled artisan that the

include suitable solvents of the active and can include

compositions set forth herein can be formulated for and

buffering agents, preservatives and the like.

adapted for use in any species of animal, including, but not

Where desirable or necessary, preserving, suspending,
thickening or emulsifying agents can be included. If

limited to equine, canine, feline, bovine, caprine, porcine
and ovine species.

intended for oral use, a bolus can be provided for large
animals With retention means to inhibit regurgitation. For

In one preferred embodiment, the invention provides a

veterinary composition comprising a pharmaceutically

example, it may be Weighed With a heavy density materials
such as iron or tungsten or the like or may be retained by its

shape, for example, by Wings Which spring after adminis
tration. Boluses may contain disintegrating agents such as
maiZe starch or calcium or sodium methylcelluloses,

5

hydroxypropylmethylcellulose, guar based vegetable gums,
sodium alginates or sodium starch glycolates; granulating or
binding agents, such as starch in the form of mucilage, starch
derivatives, such as methylcellulose, calcium stearate, talc,

gelatin or polyvinylpyrrolidone; and/or lubricating agents,

20

such as magnesium stearate or stearic acid.

Other compounds Which may be included are, for

example, medically inert ingredients, e.g. solid and liquid
diluents, such as starch or calcium phosphate for tablets,
boluses or capsules; olive oil or ethyl oleate for soft cap
sules; and Water or vegetable oil for suspensions or emul

effective amount of a guanidine derivative, e.g., guanabenZ
or guanabenZ acetate, Which useful for providing a rapid
onset and long lasting analgesia and sedation in a standing
animal, e.g., a horse. As set forth in the examples beloW, the
rapid onset and lasting duration of a single intravenous
administration of the active provides a novel and heretofore
unreported use for this family of compounds.
A particularly attractive feature of the compositions pro
vided by the invention is that the analgesia and sedation
produced by administration of the active are rapidly revers
ible. In particular, one embodiment of the invention provides
a method for selective reversal of the analgesic, and/or
tranquil and/or sedative effects via administration of a
pharmaceutically effective amount of an 0t adrenergic

25

antagonist. Examples of suitable 0t adrenergic antagonists,
include but are not limited to yohimbine, rauWolscine,

sions; lubricating agents such as talc or magnesium stearate;

idaZoxan, tolaZoline and atepameZole.

gelling agents such as colloidal clays; thickening agents

In a presently preferred embodiment, the ot adrenergic
antagonist suitable for reversal of the active is yohimbine or

such as gum tragacanth or sodium alginate; dedusting agents
such as liquid paraf?n, ?xed oils and surfactants and other
therapeutically acceptable accessory ingredients, such as

30

tolaZoline. A presently preferred dosage of yohimbine for
reversal of the active guanidine derivative is betWeen about

humectants, preservatives, buffers, and anti-oxidants, Which

0.04 to about 0.08 mg/kg IV. and the preferred dosage of

are useful as carriers in such formulations. When desired,

tolaZoline is betWeen about 2.0 to about 4.0 mg/kg I.V. One
of skill in the art can appreciate that the dosage of the

other medicaments and/ or nutrients, unless contraindicated,
may also be included.
It is also to be understood that While the preferred
formulation is formulated in unit dosage form for a single

35

administration, alternatively, the compositions of the inven
tion may be given to effect (to achieve a desired level of
sedation and/ or analgesia), administered in divided doses, or
supplemental doses administered as needed.
In particular, one embodiment of the present invention

the animal and the like.
40

tically effective amount of a guanidine derivative that is
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animal. As set forth above, the guanidine derivative can be
any of the afore-mentioned compounds or other derivatives

of guanidine provided that the selected active possesses
su?icient 0t adrenergic receptor agonist activity to be used in
accordance With the methods of the invention and provided
that the selected active does not produce unWanted side
effects in the subject animal Which will affect the long term
health of the animal.
In a preferred embodiment, the invention provides a

50

species of animal or in injectaable an form, e.g., the selected
active in a 1 mg/ml solution. In a presently preferred
embodiment, the pharmaceutically effective amount of the
quanidine derivative is about 0.25 mg/kg. In a particularly
preferred embodiment the compositions of the invention are

55

guanabenZ acetate or a pharmaceutically acceptable deriva
tive thereof and the pharmaceutically effective amount is
betWeen about 0.05 mg/kg and about 0.50 mg/kg, but is

comprised of a guanidine derivative that is guanabenZ,

especially about 0.25 mg/kg.

guanoxabenZ, clonidine, guanacline, guanadrel, guanaZod

The present invention also provides for methods of induc
ing a rapid onset and long lasting sedation and/or analgesia

ine, guanethidine, guanfacine and guanochlor, guanoxan,
60

ferred guanidine derivative is guanabenZ, guanabenZ acetate
or pharmaceutically acceptable derivatives thereof.
Of course, one of skill in the art can appreciate that the

compositions of the invention can further comprise a phar

maceutically acceptable carrier and speci?c embodiments
thereof are hereby provided. LikeWise, the present invention
provides speci?c embodiments Wherein the veterinary com

and sedation in an animal Wherein the pharmaceutically
effective amount is betWeen about 0.05 mg/kg and about
0.50 mg/kg. The compositions of the invention can be
formulated in unit dosage form, e.g., in an oral tablet
formulated on a preferred administration rate for a particular

composition Wherein the guanidine derivative is selected
from the group consisting of guanabenZ, guanabenZ acetate,
and mixtures thereof. In yet another embodiment, the pre

In a presently preferred embodiment, the invention pro
vides a veterinary composition comprised of a pharmaceu

useful for providing a rapid onset and long lasting analgesia

provides a veterinary composition comprising a pharmaceu
tically effective amount of a pharmaceutically acceptable
guanidine derivative Which is useful for providing a rapid
onset and long lasting analgesia and/or sedation in an

reversal agent Will vary depending upon, e.g., the length of
time from administration of the active, the dosage and route
of administration, the species of animal, siZe and health of
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in an animal. The methods comprise administering to the
animal a pharmaceutically effective amount of a composi
tion comprised of a guanidine derivative. As set forth above
With reference to the compositions of the invention, the
guanidine derivative can be any derivative of the guanidine
family so long as the selected derivative possesses the

requisite 0t adrenergic receptor agonist activity to produce
the desired clinical effects in the animal Without causing

US 7,074,834 B2
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undue side effects. Examples of suitable guanidine deriva

but may be especially useful in alleviating or lessening the

tives include, but are not limited to guanabenZ, guanabenZ

pain associated With colic (abdominal pain). LikeWise, the

acetate, guanoxabenZ, clonidine, guanacline, guanadrel,
guanaZodine, guanethidine, guanfacine and guanochior,

pain assocaited With acute racing injury and/ or post surgical
pain may be treated via the compositions disclosed herein.
A further appreciation of the invention may be gleaned

guanoxan and mixtures thereof. The presently preferred
methods of the invention comprise of inducing a rapid onset
and long lasting sedation and/or analgesia in an animal. The
methods comprise administering to the animal a pharma
ceutically e?fective amount of guanabenZ, guanabenZ acetate
or pharmaceutically acceptable derivatives thereof.
One of skill in the art Will appreciate that the adminis
tering step provided by the invention can be via any route,
including but not limited to oral, intravenous and intramus
cular. Further, the methods provided herein are contem

from the folloWing speci?c examples. These speci?c
examples are provided for illustration only and are not to be
regarded as restricting the invention in any Way.
EXAMPLES

Example 1

plated for use on any animal, including but not limited to

equine, canine, feline, bovine, caprine, porcine and ovine. In
a particularly preferred embodiment of the methods of the
invention the animal is a large animal, e. g., a horse or a coW,

and the sedation and analgesia are induced and maintained

While the animal is standing.

20

The compositions comprised of guanidine derivatives
administered according to the methods of the invention are
administered in pharmaceutically e?fective amounts Which
can range from betWeen about 0.05 mg/kg and about 0.50
mg/kg of the active. In one preferred embodiment, the
pharmaceutically e?fective amount of the guanidine deriva
tive is about 0.25 mg/kg.

solid circles (O - - - O) shoW head ptosis measured as cm

25

above ground level after rapid intravenous administration of
guanabenZ. Note also the rapid reversal of this tranquiliZa
tion and sedation by the administration of yohimbine (see
arroW) at a dose of 60 mg intravenously. The open circles
(0 - - - 0) shoW the rapid reversal e?fect by intravenous

injection of yohimbine.

A presently preferred method of the invention, comprises
inducing a rapid onset and long lasting sedation and/or
analgesia in an animal, comprising administering to the

GuanabenZ Produces a Rapid Onset of TranquliZation and
Sedation:
As shoWn in FIG. 1, a horse (about 1000 lbs), Was
administered guanabenZ at a dose of 0.2 mg/kg (100 mg)
intravenously at time point 0. Note hoW the dose of 100 mg
of guanabenZ yields a very rapid onset of analgesia response
as indicated by the decrease in head ptosis of the horse. The

The advantages of this approach are many fold: In the ?rst
30

place, e?fective sedative and tranquiliZing levels of guana

animal a pharmaceutically e?fective amount of a composi

benZ or a derivative thereof are attained Within minutes of

tion comprised of guanabenz, guanabenZ acetate or phar
maceutically acceptable derivatives thereof and Wherein the

the administration of the compound, Which leads to shorter
Waiting time to initiate desired procedure or treatment. In the

pharmaceutically e?fective amount is betWeen about 0.05

mg/kg and about 0.50 mg/kg but is especially about 0.25

35

mg/kg.
Of particular importance With respect to the methods for
providing long lasting sedation and/ or tranquiliZation and/or
analgesia set forth herein is the fact that the method further

provides the ability for selectively reversing or controlling

40

second place, the animal Will remain in a standing position.
Thirdly, the duration of the sedation and tranquiliZation lasts
for an extended period of time, enabling the performance of
lengthier procedures or treatments. Fourthly, the sedative
and tranquiliZing e?fect of guanabenZ or derivatives thereof
can be rapidly reversed by the administration of yohimbine
or any other alpha-2-adreno receptor antagonist.

the level of analgesia and/or sedation and/or tranquiliZation

Example 2

in the animal. The methods of the invention can therefore

further comprise the step administering a pharmaceutically
e?fective amount of 0t adrenergic receptor antagonist to the
animal to control or reverse the e?fects of the previously
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administered 0t adrenergic receptor agonists. The 0t adren
ergic receptor antagonists suitable for use in the invention
include, but are not limited to yohimbine, rauWolseine,

dose of 0.2 mg/kg (100 mg) intravenously at time point 0
(see FIG. 2). Note hoW the dose of 100 mg of guanabenZ

idaZoxan and atepameZole. Presently preferred 0t adrenergic
receptor antagonists are yohimbine or tolaZoline. Apresently
preferred dosage of yohimbine for reversal of the active
guanidine derivative administered according to the methods

50

set forth herein is betWeen about 0.04 to about 0.08 mg/kg

lamp equine analgesia model after administration of guana
55

appreciate that the dosage of the reversal agent Will vary
depending upon, e.g., the length of time from administration
of the active, the dosage and route of administration, the
species of animal, siZe and health of the animal and the like.
One of skill in the art can also appreciate that the

yields a very rapid onset of analgesia response as indicated
by the increase in desensitiZation to the heat lamp. Note also
that this response is maintained at full intensity for approxi
mately 30 minutes and declines thereafter, and returns to
control values by 6 hrs post administration. The solid circles
(O - - - O) shoW the increasing control latency in our heat

IV. and the preferred dosage of tolaZoline is betWeen about
2.0 to about 4.0 mg/kg I.V. One of skill in the art can

Analgesic Response to GuanabenZ in the Horse:
A horse (1000 lbs) in Was administered guanabenZ at a

benZ at indicated Zero time.

Example 3
60

GuanabenZ IV Produces a Transient Diuresis With a Corre

sponding Reduction in Urinary Speci?c Gravity and Tran

compositions and methods of the invention have many
applications and uses in the ?eld of veterinary medicine. In

sient Hyperglycemia and Glucosuria:

addition to providing a means for chemical restraint of

Referring noW to FIG. 3, a horse (about 1000 lbs) Was

animals, particularly large animals, the compounds may be

administered guanabenZ at a dose of 0.2 mg/kg (100 mg)
intravenously at time point 0. In FIG. 3a, note hoW the dose
of 100 mg of guanabenZ yields a transient increase in blood
glucose levels after the administration of guanabenZ. The

used in situations Whenever analgesia and/or sedation are

required. In the equine species for example, the composi
tions of the invention may be used to treat any source of pain

65
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solid circles (. - - - .) show blood glucose levels after rapid

3. The method of claim 1, Wherein the administration is
oral.
4. The method of claim 1, Wherein the administration is

intravenous administration of guanabenZ. Note also the
increase in urine glucose levels after the administration of

guanabenZ. The open circles (CD-0) shoW the correspond
ing urinary concentrations of glucose after this administra

intravenous .

5. The method of claim 1, Wherein the administration is
intramuscular.
6. The method of claim 1, Wherein the animal is selected

tion.
In FIG. 3b, note hoW the dose of 100 mg of guanabenZ
yields an increase in urine production as indicated by the
increase in volume of urine collected. The solid circles

from the group consisting of equine, canine, feline, bovine,
caprine, porcine and ovine.

(. - - - .) shoW volume of urinary output after rapid

intravenous administration of guanabenZ. Note also in FIG.
30, the decrease in speci?c gravity of the urine after the

7. The method of claim 1, Wherein the animal is an equine.
8. The method of claim 1 Wherein the rapid onset sedation
and analgesia is induced in a standing animal.
9. The method of claim 1, further comprising the step of

administration of the guanabenZ. The solid circles (. - - - .)

shoW the corresponding urinary speci?c gravity values after
this administration.

selectively reversing or controlling the level of analgesia and
sedation in the animal comprising administering a pharma

The foregoing description of a preferred embodiment of
the invention has been presented for purposes of illustration
and description. It is not intended to be exhaustive or to limit

the invention to the precise form disclosed. Obvious modi
?cations or variations are possible in light of the above
teachings. The embodiment Was chosen and described to
provide the best illustration of the principles of the invention
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antagonist is selected from the group consisting of yohim
bine, rauWolscine, idaZoxan and atepameZole.

and its practical application thereby enable one of ordinary
skill in the art to utiliZe the invention in various embodi
ments and With various modi?cations and variations are
Within the scope of the invention as determined by the

11. The method of claim 1, Wherein the pharmaceutically
effective amount of the guanidine derivative is betWeen
25

appended claims When interpreted in accordance With the
breadth to Which they are fairly, legally and equitable
entitled.
What is claimed is:

effective amount of the guanidine derivative is about 0.25
30

tering to the animal a pharmaceutically effective amount of
35

nabenZ acetate, guanoXabenZ, clonidine, guanacline, guana

drel, guanaZodine, guanethidine, guanfacine, guanochior,
and guanoxan.

2. The method of claim 1, Wherein the guanadine deriva
tive is guanabenZ acetate or pharmaceutically acceptable
derivative thereof.

about 0.05 mg/kg and about 0.50 mg/kg.
12. The method of claim 1, Wherein the pharmaceutically

mg/kg.

1. A method of inducing rapid onset and long lasting
sedation and analgesia in an animal, comprising adminis
a composition consisting essentially of a guanidine deriva
tive selected from the group consisting of guanabenZ, gua

ceutically effective amount of 0t adrenergic antagonist to the
animal.
10. The method of claim 9 Wherein the ot adrenergic
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13. The method of claim 1, Wherein the guanidine deriva
tive is guanabenZ acetate or a pharmaceutically acceptable
derivative thereof and the pharmaceutically effective
amount is betWeen about 0.05 mg/kg and about 0.50 mg/kg.
14. The method of claim 1, Wherein the guanidine deriva
tive is guanabenZ acetate or a pharmaceutically acceptable
derivative thereof and the pharmaceutically effective
amount is about 0.25 mg/kg.
15. The method of claim 1, Wherein the guanidine deriva
tive is an 0t adrenergic agonist.
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